Growth Metrics

Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles (2016 - 2024)

Lineage Cell Therapeutics' Amortizatization of Intangibles history spans 15 years, with the latest figure at $22000.0 for Q1 2024.

  • For Q1 2024, Amortizatization of Intangibles fell 33.33% year-over-year to $22000.0; the TTM value through Dec 2024 reached $22000.0, down 83.08%, while the annual FY2024 figure was $22000.0, 83.08% down from the prior year.
  • Amortizatization of Intangibles reached $22000.0 in Q1 2024 per LCTX's latest filing, down from $32000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $332000.0 in Q2 2020 to a low of -$13000.0 in Q4 2022.
  • Average Amortizatization of Intangibles over 5 years is $69647.1, with a median of $33000.0 recorded in 2021.
  • Peak YoY movement for Amortizatization of Intangibles: soared 1144.44% in 2021, then plummeted 140.62% in 2022.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $136000.0 in 2020, then tumbled by 76.47% to $32000.0 in 2021, then tumbled by 140.62% to -$13000.0 in 2022, then soared by 346.15% to $32000.0 in 2023, then tumbled by 31.25% to $22000.0 in 2024.
  • Per Business Quant, the three most recent readings for LCTX's Amortizatization of Intangibles are $22000.0 (Q1 2024), $32000.0 (Q4 2023), and $33000.0 (Q3 2023).